Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Cost burden of hepatitis C therapies high for payers

    • 1 Accesses

    This is a preview of subscription content, log in to check access.

    Notes

    1. 1.

      2016 US dollars

    Reference

    1. van Boemmel-Wegmann S, et al. Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection. Digestive Diseases and Sciences : 14 Jan 2020. Available from: URL: http://doi.org/10.1007/s10620-019-06037-z

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Cost burden of hepatitis C therapies high for payers. PharmacoEcon Outcomes News 846, 8 (2020). https://doi.org/10.1007/s40274-020-6547-5

    Download citation